Innovent Biologics, ASK Pharm announce China’s NMPA approval of limertinib to treat metastatic EGFR T790M-mutated NSCLCr: San Francisco Saturday, January 18, 2025, 09:00 Hrs [IS ...

Pioneer Natural Resources’ former CEO and Hess’s CEO are prohibited from serving on the oil companies’ boards ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

A judge has dismissed New York City's lawsuit seeking to hold Exxon Mobil , BP and Shell liable for misleading the public ...

New York court dismisses NYC lawsuit against Exxon, BP, and Shell over climate change deception claims, citing lack of proof of greenwashing.

The Food and Drug Administration has accepted and granted priority review to a new drug application for sunvozertinib.

This latest approval for Orpathys in NSCLC makes the drug available in both the first- and second-line settings.

ORIC Pharmaceuticals (ORIC) announced that the company has entered into a supply agreement with Janssen Research & ...

Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug Application for ORPATHYS® (savolitinib) has been granted approval by the China National Medical Products ...

Chinese biopharma Hutchmed today announced that the supplemental New Drug Application for Orpathys (savolitinib) has been ...

Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug Application for ORPATHYS ® (savolitinib) has been granted approval by the China National Medical ...